Discussion
The long term survival of people who retire early at ages 55 or 60 is no better than that of those who retire at 65. On the contrary, mortality improved with increasing age at retirement for people from both high and low socioeconomic groups, defined according to employment grade. It is reasonable to assume that some workers retired at 55 because of failing health, as the mortality for this group in the first 10 years after retirement was almost twofold higher than that of their peers who continued working. The health status of those who retired at 60, however, was similar to those who continued working at 60.
The finding of lower survival among employees of low socioeconomic status, regardless of age at retirement, is not unexpected and is consistent with other studies. [8] [9] [10] [11] Similarly, it was not unexpected that men had statistically higher mortality than women and that those retiring in more recent years had better survival.
Several studies found lower survival among those retiring early and attributed this to poor health status forcing early retirement. 1 3 Our study confirmed the finding of lower survival in people who take early retirement at age 55, but we did not find evidence of lower survival among those who retired at 60. To reduce potential bias due to differences in health status between early and late (age 65) retirees, we excluded survival for the first 10 years of follow-up after retirement at 55 and for the first five years after retirement at 60 for early retirees. Although the effect of early retirement because of failing health may not be totally eliminated, survival rates remained significantly greater for those who retired at 65 compared with those who retired at 55. The difference in survival between those who retired between 60 and 65 was, however, small and not statistically significant. The first HIV seroconversion in the United Kingdom in a man with haemophilia was in 1979. 1 After HIV was identified, measures were taken to remove the risk of HIV transmission via blood products, and since 1986 no HIV infections have occurred through this route in the developed world. The epidemic is now 25 years old in haemophilic men. Although the introduction of highly active antiretroviral therapy (HAART) has altered the course of HIV infection, many haemophilic men died before this became available. It is important to monitor those remaining alive to determine their long term outcomes and to assess the impact of coinfection with hepatitis C virus.
Participants, methods, and results
The Royal Free Hospital haemophilia cohort, consisting of 111 men with haemophilia infected with HIV after treatment with contaminated clotting factor concentrates (median age 22 (range 2-77) years at infection), has been described previously. 2 All are coinfected with hepatitis C virus. Follow-up timecalculated from seroconversion date to the date of death, last clinic visit (for those lost to follow-up), or
What is already known on this topic
There is a widespread perception that early retirement is associated with longer life expectancy and later retirement is associated with early death No consensus has been reached on the comparative survival or mortality of people who retire early or late
What this study adds
Early retirement at 55 or 60 is not associated with increased survival Employees who retired at 60 had similar survival to those who retired at 65
Differences in mortality could not be attributed to the effects of sex, year of entry to the study, or socioeconomic status In 1989, using a method based on rates of CD4 cell count decline, we estimated that 60 men would have AIDS by 2000 (table) . 3 The observed numbers are remarkably consistent with these estimates, which is somewhat surprising as we had not anticipated the benefits of HAART. Possible explanations are that those who survived long enough to benefit from HAART had not been predicted to develop AIDS before 2000 in any case, and that any positive effects of HAART have been partly negated by the effects on survival of liver disease.
The 23 patients remaining under care at the centre (14 patients have transferred elsewhere) have been followed for a median of 22.7 (19.7-25.1) years. Most (20) have received HAART, 14 of whom had already had antiretroviral treatment when starting HAART. The 20 patients have received a median of seven (3-11) antiretroviral drugs and have been exposed to antiretroviral therapy for a median of 9.9 (1.0-16.8) years. Although these patients' treatment histories would now be considered suboptimal, all currently have an HIV RNA level < 50 copies/ml and their median CD4 cell count is 326 (139-593) × 10 6 cells/l. The three patients who have not received HAART have had stable CD4 counts > 200×10 6 cells/l; viral loads have remained low in two patients, and moderate but stable (last viral load 18 234 copies/ml) in the third.
Comment
A small proportion of haemophilic men infected with HIV 20-25 years ago remain alive and well. Advances in haemophilia care had increased life expectancy from 40 years in the 1960s to 69 years by 1980. 4 The HIV epidemic caused a reversal in these improvements that has been reversed only partially by HAART because coinfection with hepatitis C virus continues to cause deaths. 5 Although treatment of hepatitis C is improving, responses remain poor among those coinfected with HIV. Continued development of new antiviral agents for both HIV and hepatitis C virus is essential to maintain the health of these patients.
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